Actuate Therapeutics, INC 10-Q quarterly reports

Actuate Therapeutics reported a net loss of $5.6 million for Q1 2026, with a decrease in R&D spending and ongoing concerns about its ability to continue as a going concern beyond July 2026.

Actuate Therapeutics reported its Q3 2025 results, showcasing positive topline data from its Phase 2 mPDAC trial for elraglusib and detailing recent capital raises to fund ongoing operations.

Actuate Therapeutics reported promising Phase 2 results for elraglusib in pancreatic cancer but faces substantial doubt about its ability to continue as a going concern beyond October 2025.

Actuate Therapeutics reports a net loss for Q1 2025 and expresses substantial doubt about its ability to continue as a going concern without additional funding.

Actuate Therapeutics reports its third quarter 2024 financial results, highlighting its transition to a public company following a successful IPO and continued clinical development of elraglusib.

Actuate Therapeutics, a clinical-stage biopharmaceutical company, released its second quarter 2024 financial results, highlighting ongoing clinical trials and recent corporate developments including its IPO.